Compare Eli Lilly And Co (LLY) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Vital Farms Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Vital Farms Inc trades at $9.33 (market cap $405.27M). The key difference: Eli Lilly And Co is far larger — about 2566.2× Vital Farms Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Vital Farms Inc for 14 Days on average.
| LLY | VITL | |
|---|---|---|
Market Cap | $1.04T | $405.27M |
Volume | 3,064,878 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $1.28K | $43.68 |
52-Week Low | $799.57 | $8.28 |
Typical Hold Time | 93 Days | 14 Days |
Enterprise Value | $1.09T | $492.28M |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Vital Farms (VITL) trades at $9.435, up 2.11% today, amid a challenging period marked by volatile earnings and a bearish technical signal. The stock shows weak profitability with a net income margin of 0.02% in 2026, though valuation ratios like P/S of 0.55 appear attractive. Recent news highlights strategic review for a potential sale, with price targets ranging from $10 to $20. Cash flow remains negative, driven by heavy investing activities, while institutional interest persists with new acquisitions.
The outlook is mixed: analyst consensus is bullish with a $13.11 target, but near-term risks include pricing pressure in the egg market and earnings volatility. Recovery hinges on stabilizing supply costs and executing strategic options. Investors should weigh low valuation against operational challenges and industry headwinds for potential upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
